基本信息
浏览量:384
职业迁徙
个人简介
Dr. Higano is an internationally renowned expert and clinical researcher focusing on prostate cancer. At UW, she led the prostate cancer clinical research group that participated in developing agents such as zoledronic acid, sipuleucel-T, enzalutamide, apalutamide, abiraterone, radium 223. Over these years, her clinical research has impacted the standards of care for patients with prostate cancer. She is a passionate educator and mentor and has guided many fellows and young faculty at the University of Washington and elsewhere who have chosen an academic career in GU Oncology.
Her research interest include: New agents for treatment of prostate cancer; use of intermittent androgen deprivation therapy (ADT); the effect of ADT and intermittent ADT on cognition, bone density, lipids, testosterone recovery, time to develop castration resistance; the effect of exercise to attenuate the effects of ADT; new drug development and clinical design; immunotherapy for prostate cancer.
Her research interest include: New agents for treatment of prostate cancer; use of intermittent androgen deprivation therapy (ADT); the effect of ADT and intermittent ADT on cognition, bone density, lipids, testosterone recovery, time to develop castration resistance; the effect of exercise to attenuate the effects of ADT; new drug development and clinical design; immunotherapy for prostate cancer.
研究兴趣
论文共 644 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
The Prostate (2024)
CANCER (2024)
Kate L Mahon,Sarah Im Sutherland,Hui Ming Lin,Martin R Stockler,Howard Gurney,Girish Mallesara, Karen Briscoe,Gavin Marx,Celestia S Higano, Johann S de Bono,Kim N Chi,Georgina Clark,
The Prostate (2024)
JU Open Plusno. 4 (2024)
JU Open Plusno. 4 (2024)
JOURNAL OF SEXUAL MEDICINEno. Supplement_1 (2023)
引用0浏览0引用
0
0
crossref(2023)
CURRENT OPINION IN UROLOGYno. 5 (2023): 396-403
引用0浏览0WOS引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn